NasdaqGS:UTHRBiotechs
Is United Therapeutics (UTHR) Attractive After Recent Pullback And Strong Multi Year Gains?
If you are trying to work out whether United Therapeutics at about US$472 per share looks expensive or reasonable, you are in the right place.
The stock has been flat over the last 7 days, with a 7.5% decline over the past month and a 5.0% decline year to date, set against a 26.9% return over 1 year, 78.7% over 3 years and 187.2% over 5 years.
Recent coverage around United Therapeutics has focused on how the company is positioned within the pharmaceuticals and biotech space and how investors...